Home » USA Broker Ratings » Amgen Inc. – Consenus Indicates Potential 9.6% Upside

Amgen Inc. – Consenus Indicates Potential 9.6% Upside

Amgen Inc. found using ticker (AMGN) now have 19 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 243 and 173 calculating the average target price we see 214.84. With the stocks previous close at 196.08 this indicates there is a potential upside of 9.6%. There is a 50 day moving average of 199.22 while the 200 day moving average is 186. The company has a market cap of $117,977m. Find out more information at: http://www.amgen.com

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; Syapse; and DaVita Inc., as well as strategic research partnership with the University of Washington’s Institute for Protein Design. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Join us on our new LinkedIn page

Follow us on LinkedIn